Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma

American Journal of Surgical Pathology

Volumn 39, Issue 3, 2015, Pages 287-293

  Howitt, Brooke E ^a   Hanamornroongruang, Suchanan ^c   Lin, Douglas I ^a   Conner, James E ^a   Schulte, Stephanie ^a   Horowitz, Neil ^a,b   Crum, Christopher P ^a   Meserve, Emily E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

BRCA; endometrioid; fallopian tube; neoplasia; risk reduction salpingo oophorectomy; serous carcinoma; tubal intraepithelial carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGE; AGED; BIOLOGICAL MODEL; CANCER GRADING; CARCINOMA IN SITU; CLINICAL TRIAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; NUCLEOTIDE SEQUENCE; OVARIAN NEOPLASMS; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BOSTON; BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOMA IN SITU; DNA MUTATIONAL ANALYSIS; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MODELS, BIOLOGICAL; MUTATION; NEOPLASM GRADING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84924071135     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000369     Document Type: Article

References (25)

1. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456.
2. Crum CP, Herfs M, Ning G, et al. Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer. J Pathol. 2013;231:402-412.
3. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169.
4. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol. 2008;27:1-9.
5. Vang R, Visvanathan K, Gross A, et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol. 2012;31:243-253.
6. Levanon K, Ng V, Piao HY, et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene. 2010;29:1103-1113.
7. Perets R, Wyant GA, Muto KW, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 2013;24: 751-765.
8. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35.
9. Powell CB, Swisher EM, Cass I, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol. 2013;129:364-371.
10. Conner JR, Meserve E, Pizer E, et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingooophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol. 2014;132:280-286.
11. Gilbert L, Basso O, Sampalis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. 2012;13:285-291.
12. Kö bel M, Kalloger SE, Lee S, et al. Ovarian Tumor Tissue Analysis consortium. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev. 2013;22:1677-1686.
13. Roh MH, Yassin Y, Miron A, et al. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol. 2010;23:1316-1324.
14. Soslow RA, Han G, Park KJ, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol. 2012;25:625-636.
15. Rabban JT, Garg K, Crawford B, et al. Early detection of highgrade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol. 2014;38:729-742.
16. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009;6:e1000114.
17. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple negative breast cancer. Clin Breast Cancer. 2009;9(suppl 2):S73-S81.
18. Dabbs DJ, Chivukula M, Carter G, et al. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol. 2006;19:1506-1511.
19. Kurbel S. In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer. Tumour Biol. 2013;34:1-7.
20. Abdel-Fatah TM, Powe DG, Hodi Z, et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 2008;32:513-523.
21. Turashvili G, Hayes M, Gilks B, et al. Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer? Virchows Arch. 2008;452:589-598.
22. Espinosa I, Catasus L, Canet B, et al. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Mod Pathol. 2011;24:846-854.
23. George J, Alsop K, Etemadmoghadam D, et al. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res. 2013;19:3474-3484.
24. Merritt MA, Bentink S, Schwede M, et al. Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes. PLoS One. 2013;8:e80314.
25. Auersperg N. The stem-cell profile of ovarian surface epithelium is reproduced in the oviductal fimbriae, with increased stem-cell marker density in distal parts of the fimbriae. Int J Gynecol Pathol. 2013;32:444-453.